Reactions 1664, p4 - 12 Aug 2017 Serious ADRs with ocular triamcinolone/moxifloxacin product A compounded drug product containing triamcinolone (i.e. steroid) and moxifloxacin (i.e. anti- infective) is associated with serious ADRs, according to a US FDA Safety Alert. This product – which is compounded by Guardian Pharmacy Services (Dallas, Texas) – is intended for intravitreal injection following cataract surgery for postoperative prophylaxis of ocular inflammation and endophthalmitis; the expectation is that the patient would not require postoperative eye drops. The FDA received adverse event (AE) reports on 5 April and 1 June this year relating to at least 43 patients who had received intravitreal injections of the above- mentioned triamcinolone/moxifloxacin product following cataract surgery, which was performed at two different surgery centres in Dallas. Several months after their operations, these patients developed a variety of symptoms, including: vision impairment, poor night vision, loss of colour perception, photophobia, glare, halos, flashing lights, ocular discomfort, pain, loss of balance, headaches, and/or nausea. Some of these AEs mentioned did not occur until at least 1 month following the cataract surgery. During follow-up examinations of patients treated at the Park Central Surgical Center, physicians found that patients who received the triamcinolone/moxifloxacin product experienced decreased visual function that involved visual acuity and visual fields. Initial optical tests revealed macular oedema, followed by some cases of retinal degeneration. During the 5-month postoperative period, some patients reported symptom improvements, but a number of patients continued to experience "a significant reduction in best-corrected visual acuity and visual fields", stated the FDA. Both patients and healthcare professionals are encouraged to report AEs related to this compounded triamcinolone/moxifloxacin product to the FDA’s MedWatch programme. US Food and Drug Administration. Compounded Triamicinolone and Moxifloxacin Product for Intravitreal Injection by Guardian Pharmacy Services: Alert to Health Professionals - Serious Adverse Events Reported. Internet Document : 28 Jul 2017. Available from: URL: https://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm569123.htm 803263660 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664
Reactions Weekly – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera